Tevogen Bio Holdings Inc. (TVGN) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Tevogen Bio reported revenue of $0. Net income was -$26.3M, or -$8.08 per diluted share. Operating activities generated -$12.3M of cash, leaving -$12.4M of free cash flow. At fiscal year end, Tevogen Bio held $4.4M in total assets against $12.6M in total liabilities, including $0 of cash and equivalents.
Open the full interactive Tevogen Bio financials → Quarterly statements, key ratios, valuation history and price charts.
Tevogen Bio Key Stats
| Share Price | $7.11 |
|---|---|
| Market Cap | $27.2M |
| 52-Week Range | $3.89 – $37.75 |
| Shares Outstanding | 3.8 million (basic, 2026 Q2) |
Tevogen Bio Income Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Income | — | — | -$53.6M | -$26.1M |
| Pre-Tax Income | $4.4M | -$67,325 | -$13.7M | -$26.3M |
| Income Tax | — | — | — | $4,750 |
| Net Income | $4.4M | -$67,325 | -$13.7M | -$26.3M |
| Diluted EPS | $4.50 | -$0.27 | -$3.50 | -$8.08 |
Tevogen Bio Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$5.7M | -$4.7M | -$5.4M | -$5.8M |
| Diluted EPS | -$1.50 | -$1.41 | -$1.61 | -$1.52 |
Tevogen Bio Balance Sheet
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash & Equivalents | $129,186 | — | $0 | $0 |
| Current Assets | $274,356 | $355,836 | $2.4M | $1.5M |
| Total Assets | $357.1M | $17.0M | $3.5M | $4.4M |
| Current Liabilities | $350,454 | $3.0M | $9.0M | $7.1M |
| Total Liabilities | $15.1M | $17.7M | $10.1M | $12.6M |
| Shareholders' Equity | -$14.8M | -$17.4M | -$6.7M | -$8.2M |
Tevogen Bio Cash Flow Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash From Operations | -$215,395 | -$1.4M | -$12.0M | -$12.3M |
| Cash From Investing | — | $342.9M | — | -$64,439 |
| Cash From Financing | — | -$341.7M | $12.2M | $11.7M |
| Free Cash Flow | — | — | -$12.1M | -$12.4M |
Figures from Tevogen Bio's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Tevogen Bio financials page for every line item.
Tevogen Bio Company Profile
| Ticker | TVGN |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Warren, New Jersey |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001860871 |
Frequently Asked Questions
What was Tevogen Bio's revenue in fiscal 2025?
Tevogen Bio (TVGN) reported revenue of $0 for fiscal 2025.
What is Tevogen Bio's annual revenue history?
Tevogen Bio's annual revenue by fiscal year: 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Tevogen Bio's net income in fiscal 2025?
Tevogen Bio reported net income of -$26.3M for fiscal 2025.
What was Tevogen Bio's earnings per share (EPS) in fiscal 2025?
Tevogen Bio's diluted EPS was -$8.08 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Tevogen Bio generate in fiscal 2025?
Tevogen Bio generated -$12.4M of free cash flow in fiscal 2025.
What was Tevogen Bio's revenue last quarter?
In its most recent reported quarter (2026 Q2), Tevogen Bio reported revenue of $0.
How many shares of Tevogen Bio are outstanding?
Tevogen Bio reported a weighted average of 3.8 million basic shares outstanding in 2026 Q2.
What is Tevogen Bio's market cap?
Based on its latest closing price, Tevogen Bio (TVGN) has a market capitalization of about $27.2M.
When does Tevogen Bio's fiscal year end?
Tevogen Bio's fiscal year end, as registered with the SEC, is December 31.
Where is Tevogen Bio headquartered?
Tevogen Bio lists its business address in Warren, New Jersey in its SEC filings.